Weill Cornell Breast Center

09/15/2026

Dr. Massimo Cristofanilli spoke with Healio about the recent U.S. Food and Drug Administration approval of camizestrant in combination with a CDK4/6 inhibitor for advanced with ESR1 mutations:

The FDA has granted accelerated approval to camizestrant in combination with a CDK4/6 inhibitor for adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer.The approval for camizestrant (Etcamah, AstraZeneca) is dependent on the detection of an ESR1 mutation...

07/20/2026

Congratulations to Dr. Eleni Andreopoulou for being the first woman to receive an honorary professorship from her alma mater in Greece! https://bit.ly/3T6gD1q

06/07/2026

June is . More people are being diagnosed with and surviving cancer than ever before. More people are also being diagnosed with cancer at younger ages. These trends along with advances in cancer treatments and technologies, have led to over 19 million survivors worldwide. Dr. Emily Tonorezos, Director of the Iris Cantor Survivorship Program at Weill Cornell Medicine, joined the CancerCast podcast to discuss the growing field of cancer survivorship, emerging areas of survivorship research, and what it means for patients to live well after a cancer diagnosis.

Podcast Episode · CancerCast · June 5 · 1 sec

06/02/2026

Today at : Dr. Massimo Cristofanilli was part of a phase 3 study evaluating a new treatment combination for people with advanced hormone-receptor (HR) positive and HER2-negative : https://bit.ly/43vXTtV

06/02/2026

Final results from the SERENA-6 evaluating camizestrant for advanced patients with ESR1 mutations was presented this afternoon at . Dr. Massimo Cristofanilli shares insights: https://bit.ly/4wJVbOS

06/01/2026

Dr. Emily Tonorezos, Director of the Iris Cantor Survivorship Program Weill Cornell Medicine, was involved with shared at examining emergency department visits & hospitalizations in survivors with disabilities: https://bit.ly/43xkDcW

05/07/2026

Learn more about Dr. Vered Stearns, Chief of Breast Medical Oncology, and the path that led her to becoming a physician and conducting important to improve the lives of those with through personalized treatment approaches.

04/30/2026

To help survivors thrive long after completion of treatment for their disease, Weill Cornell Medicine/NewYork-Presbyterian Hospital created the Iris Cantor Breast Cancer Survivorship Program. Learn more about what the program offers:

More individuals are surviving cancer than ever before. The overall five-year survival rate across all cancers in the United States has reached an historic 70%, translating to nearly 19 million cancer survivors nationwide, including more than four million breast cancer survivors.1 To help breast can...

03/18/2026

Dr. Carolina Reduzzi & team published new Weill Cornell Medicine in Science Translational Medicine showing that a type of circulating tumor cell called a dual-positive (DP) cell is associated with shorter survival time in patients with advanced , especially triple-negative breast cancer:

An enigmatic type of circulating tumor cell called a dual-positive cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators at Weill Cornell Medicine.

03/16/2026

Dr. Emily Tonorezos, Director of the Iris Cantor Survivorship Program Weill Cornell Medicine, gives insight into Stage 0 , known as ductal carcinoma in situ ( ), and the symptoms, risk factors, and treatment options:

An expert explains what to know about ductal carcinoma in situ (DCIS), a Stage 0 breast cancer that is on the rise.